8 results match your criteria: "University of Louisiana at Monroe School of Pharmacy[Affiliation]"

Purpose: To develop, implement, and evaluate the effect of a faculty engagement and professional growth program targeted at junior faculty members.

Educational Activity: A faculty engagement and growth program based on adult learning theory was piloted in a clinical sciences department. Effect of the model was evaluated using a pre/post-survey evaluating faculty output and work engagement using the Utrecht Work Engagement Scale (UWES).

View Article and Find Full Text PDF

Design, implementation, and evaluation of an online elective course on current topics in pharmacy.

Curr Pharm Teach Learn

July 2017

Department of Clinical Sciences, Director of Professional Affairs, Office of Student and Professional Affairs, University of Louisiana at Monroe School of Pharmacy, United States. Electronic address:

Introduction: To describe the design and implementation of the Current Topics in Professional Pharmacy online elective course and evaluate the degree to which the course improved student pharmacists' awareness of and interest in current topics affecting the profession of pharmacy.

Methods: A one-credit hour online summer elective included weekly modules of current topics affecting the profession of pharmacy, along with a longitudinal final project in which students created their own current topic module. Each module consisted of assigned reference materials and online discussion forum posts to answer discussion questions and share professional opinions.

View Article and Find Full Text PDF

To describe grittiness of students from three pharmacy schools and determine if grit is associated with academic performance measures. Pharmacy students completed an electronic questionnaire that included the Short Grit Scale (Grit-S). Associations were determined using logistic regression.

View Article and Find Full Text PDF

Dizziness is a common yet imprecise symptom. It was traditionally divided into four categories based on the patient's history: vertigo, presyncope, disequilibrium, and light-headedness. However, the distinction between these symptoms is of limited clinical usefulness.

View Article and Find Full Text PDF

Objective. To describe the implementation and effect of an emergency preparedness laboratory activity on student knowledge, willingness to participate in emergency preparedness training, current level of preparedness, and the importance of a pharmacist's role in disaster response. Design.

View Article and Find Full Text PDF

Objective: To improve examination item quality by educating and involving course instructors in evidence-based item review and encouraging use of this process in future courses.

Methods: A peer-review process was implemented in a 2-course sequence (intervention) that involved training and review sessions before each examination and was compared to the previous year's courses (control). Instructors completed a presurvey and postsurvey on training, experience, self-confidence, and self-rated success in multiple-choice item writing.

View Article and Find Full Text PDF

Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.

Am J Health Syst Pharm

June 2015

Gary W. jean, Pharm.D., BCOP, is Assistant Professor of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo. Jill M. Comeau, Pharm.D., BCOP, is Assistant Professor of Clinical Sciences, University of Louisiana at Monroe School of Pharmacy, and Gratis Assistant Professor of Internal Medicine, Feist-Weiller Cancer Center and Inpatient Bone Marrow Transplant Unit, LSU Health-Shreveport, Shreveport, LA.

Purpose: The pharmacology, pharmacokinetics, safety and efficacy, and place in therapy of obinutuzumab in the treatment of chronic lymphocytic leukemia (CLL) are reviewed.

Summary: Obinutuzumab, a fully humanized monoclonal antibody that targets the CD20 receptor on mature B cells, was recently approved for use in combination with chlorambucil in patients with previously untreated CLL. In a Phase III clinical trial including 671 patients with CLL and significant comorbidities, patients who received obinutuzumab-chlorambucil combination therapy had longer median progression-free survival than those who received rituximab plus chlorambucil (26.

View Article and Find Full Text PDF